



Detection of idiosyncratic drug-induced liver injury (iDILI) with the GenuineSelect-TOX system




- Minimum cohort size: 24 individuals
- Doses: 10
- Replicates: 3
- Readout: cell viability

A comparative study of troglitazone and its non-iDILI partner compound rosiglitazone to mediate iDILI



GenuineSelect-TOX is more sensitive and accurate than existing preclinical models to detect DILI risk



Benefits:

- Test for iDILI risk on a tailored cohort of individuals
- Get insights on age- and sex-associated iDILI risk
- The model could detect immune-mediated idiosyncratic DILI risk
- De-risk iDILI already at preclinical stage
- Quick toxicity screenings to identify the most toxic drugs
- · Assess inter-individual differences in iDILI occurrence
- Improved preclinical selection of drug candidates for clinical development
- Reduced times and costs of drug development
- Direct translation of findings to patients



Cherradi *et al.*, 2023 In vitro models

PredictCan Biotechnologies SAS, Montpellier, FRANCE